PROHANCE gadoteridol 4189.5mg/15mL injection syringe Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

prohance gadoteridol 4189.5mg/15ml injection syringe

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; trometamol; calteridol calcium - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years of ge for enhancement of magnetic images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

PROHANCE gadoteridol 2793mg/10mL injection syringe Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

prohance gadoteridol 2793mg/10ml injection syringe

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; calteridol calcium; trometamol; sodium hydroxide; water for injections - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

PROHANCE gadoteridol 5586mg/20mL injection vial Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

prohance gadoteridol 5586mg/20ml injection vial

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; calteridol calcium; trometamol; hydrochloric acid; water for injections - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 years ofage for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

PROHANCE gadoteridol 4189.5mg/15mL injection vial Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

prohance gadoteridol 4189.5mg/15ml injection vial

bracco pty ltd - gadoteridol, quantity: 279.3 mg/ml - injection, solution - excipient ingredients: trometamol; sodium hydroxide; calteridol calcium; water for injections; hydrochloric acid - do not freeze (syringe only). prohance is indicated for use in adults and children from 2 yaers of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity. prohance can also be used for whole body mri.

FLUTICASONE SALMETEROL CIPHALER 500/50 fluticasone propionate 500 microgram / salmeterol (as xinfoate) 50 microgram powder for inhalation blister pack Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

fluticasone salmeterol ciphaler 500/50 fluticasone propionate 500 microgram / salmeterol (as xinfoate) 50 microgram powder for inhalation blister pack

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg (equivalent: salmeterol, qty 0.05 mg); fluticasone propionate, quantity: 0.5 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: ?patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids ?patients who are symptomatic on current inhaled corticosteroid therapy,for the symptomatic treatment of patients with severe copd (fev1 <50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone salmeterol ciphaler 500/50 is not indicated for the initiation of bronchodilator therapy in copd.

NEOSTIGMINE JUNO neostigmine methylsulfate 2.5 mg/1 mL solution for injection ampoule Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

neostigmine juno neostigmine methylsulfate 2.5 mg/1 ml solution for injection ampoule

juno pharmaceuticals pty ltd - neostigmine methylsulfate, quantity: 2.5 mg - injection, solution - excipient ingredients: water for injections; sodium chloride - neostigmine is indicated for:,? reversal of the effects of non-depolarising neuromuscular blocking agents.,? prophylaxis and treatment of post-operative intestinal atony and urinary retention.,? treatment of myasthenia gravis during acute exacerbations, when the condition is severe or in neonates.